<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711464</url>
  </required_header>
  <id_info>
    <org_study_id>200715868-1</org_study_id>
    <nct_id>NCT00711464</nct_id>
  </id_info>
  <brief_title>Modafinil Effects on Cognition in Schizophrenia Patients</brief_title>
  <acronym>InO</acronym>
  <official_title>A Dose-response Study of Modafinil Effects on Cognition in Schizophrenia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This
      includes many types of cognitive dysfunction, such as in attention, memory and language.
      These problems may explain why patients with schizophrenia think and act in unusual ways, and
      often have problems managing aspects of their lives that healthy adults take for granted.
      Unfortunately, the biochemical aspects of these dysfunctions are presently unknown, and it is
      not clear whether current psychiatric medications can improve these functions. A recent
      FDA-approved medication that may improve this function is modafinil. Studies in animals and
      healthy adults show that this medication can improve many of these cognitive functions. We
      plan to study the effects of modafinil on these cognitive processes, by giving various doses
      of this medication to patients before they perform tasks of these cognitive processes. We
      predict that when patients receive modafinil, they will perform better on a cognitive test,
      and that these benefits will depend on the dose given.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a disorder of cognition. The cognitive deficits of schizophrenia are present
      at the onset of the disorder, prior to medication exposure, are persistent during periods of
      remission, and are strongly related to functional outcome. These deficits prominently include
      prefrontal cortex-dependent functions. While existing medications effectively treat psychotic
      symptoms, they exhibit modest benefit at best for cognitive dysfunction. Studies of cognition
      in animal models indicate that the neurotransmitter systems that mediate many cognitive
      processes are not generally augmented by existing antipsychotic medications. Therefore,
      advances in the treatment of schizophrenia will require the study of agents with novel
      pharmacological profiles to establish their potential to remediate cognitive dysfunction.

      This study will evaluate the effects of modafinil on the range of cognitive processes known
      to be disturbed in schizophrenia. Modafinil is an FDA-approved medication with a unique
      pharmacological profile and an increasing range of off-label indications. Its neurochemical
      effects in animal models include elevation of extracellular dopamine (DA), noradrenaline (NA)
      and glutamate in the neocortex. This profile is favorable for the enhancement of cognitive
      processes. These neurochemical effects also appear to be selective for cortical versus
      subcortical brain regions, suggesting that modafinil may have minimal effects on psychotic
      symptoms, or extrapyramidal, autonomic and hormonal side effects. In addition, it differs
      from amphetamine in structure, neurochemical profile and behavioral effects, with a lower
      risk of addictive or cerebrovascular effects. Recent studies in animal models, healthy adults
      and adults with psychiatric and neurological disorders indicate that modafinil improves
      prefrontal cognitive functions. This suggests that modafinil is a leading candidate for the
      treatment of cognitive dysfunction in schizophrenia. We aim to test modafinil effects on the
      remediation of deficits in cognition in individuals with schizophrenia. We will vary the dose
      within each participant to evaluate dose-response relationships, and directly compare
      cognition outcome measures for sensitivity to drug effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Performance</measure>
    <time_frame>3-5 hours</time_frame>
    <description>Percent Accuracy on high-control (i.e. difficult) condition on test of cognitive control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>3-5 hours</time_frame>
    <description>systolic blood pressure in mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>3-5 hours</time_frame>
    <description>beats per minute</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil 100 milligrams oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil 200 mg oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil 400 mg oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil (M1, M2, M4)</intervention_name>
    <description>modafinil 100, 200, and 400 mg oral dose</description>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_label>200 mg</arm_group_label>
    <arm_group_label>400 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults age 18-54

          -  diagnosis of schizophrenia or schizoaffective disorder, or healthy with no personal or
             family history of mental illness

          -  able to provide informed consent

        Exclusion Criteria:

          -  history of significant head injury or other neurological illness

          -  active psychiatric illness requiring significant acute care

          -  significant intellectual impairment (e.g. standardized full-scale IQ &lt; 70)

          -  history of medical illness or treatment that is associated with significant increase
             in risk from modafinil treatment (e.g. cardiac disease)

          -  significant active substance abuse

          -  active pregnancy

          -  active treatment with medications that have drug interactions with modafinil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Minzenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis School of Medicine</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2008</study_first_posted>
  <results_first_submitted>May 3, 2017</results_first_submitted>
  <results_first_submitted_qc>August 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2017</results_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Michael Minzenberg, MD</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <keyword>cognition, pharmacology, memory, attention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>modafinil 100 milligrams oral dose, 200 milligrams oral dose, 400 milligrams oral dose, and placebo, in randomly sequenced dosing periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose, and placebo, in random sequence.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Performance</title>
        <description>Percent Accuracy on high-control (i.e. difficult) condition on test of cognitive control</description>
        <time_frame>3-5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>100 mg</title>
            <description>modafinil 100 milligrams oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O2">
            <title>200 mg</title>
            <description>modafinil 200 mg oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O3">
            <title>400 mg</title>
            <description>modafinil 400 mg oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single oral placebo capsule
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Performance</title>
          <description>Percent Accuracy on high-control (i.e. difficult) condition on test of cognitive control</description>
          <units>percentage correct of all trials</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="22.8"/>
                    <measurement group_id="O2" value="75.5" spread="26.8"/>
                    <measurement group_id="O3" value="67.2" spread="33.2"/>
                    <measurement group_id="O4" value="77.1" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>systolic blood pressure in mm Hg</description>
        <time_frame>3-5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>100 mg</title>
            <description>modafinil 100 milligrams oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O2">
            <title>200 mg</title>
            <description>modafinil 200 mg oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O3">
            <title>400 mg</title>
            <description>modafinil 400 mg oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single oral placebo capsule
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>systolic blood pressure in mm Hg</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="16"/>
                    <measurement group_id="O2" value="112" spread="14"/>
                    <measurement group_id="O3" value="116" spread="16"/>
                    <measurement group_id="O4" value="111" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>beats per minute</description>
        <time_frame>3-5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>100 mg</title>
            <description>modafinil 100 milligrams oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O2">
            <title>200 mg</title>
            <description>modafinil 200 mg oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O3">
            <title>400 mg</title>
            <description>modafinil 400 mg oral dose
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single oral placebo capsule
modafinil (M1, M2, M4): modafinil 100, 200, and 400 mg oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>beats per minute</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="10"/>
                    <measurement group_id="O2" value="81" spread="12"/>
                    <measurement group_id="O3" value="86" spread="16"/>
                    <measurement group_id="O4" value="76" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 hours post-dose on treatment days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>100 mg</title>
          <description>modafinil 100 milligrams oral dose</description>
        </group>
        <group group_id="E2">
          <title>200 mg</title>
          <description>modafinil 200 mg oral dose</description>
        </group>
        <group group_id="E3">
          <title>400 mg</title>
          <description>modafinil 400 mg oral dose</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Single oral placebo capsule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="00" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Minzenberg, MD</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>(310) 825-7642</phone>
      <email>MMinzenberg@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

